Patients with extensive middle-cerebral-artery stroke may benefit somewhat from hemicraniectomy, based on research published March 20 in the New England Journal of Medicine. The study found the procedure improved survival, but left many patients with considerable disability. 

C. R. Bard, Inc. (NYSE: BCR) today announced the enrollment of the first patient into the Lutonix(r) In-Stent Restenosis (ISR) Clinical Trial.  Dr. Carlos Mena, Medical Director, Vascular Medicine at Yale - New Haven Hospital, is the principal investigator of the pivotal multi-center randomized Investigational Device Exemption (IDE) trial which is expected to enroll several hundred patients at 30 sites in the U.S.

Many American women may not be aware of the warning signs of stroke, according to a study published online March 19 in Stroke. Awareness may be especially low among Hispanic women.

AstraZeneca (NYSE: AZN) today announced it has completed patient enrollment approximately four months ahead of plan in the Phase III clinical trial EUCLID studying BRILINTA(r) (ticagrelor) tablets. Part of PARTHENON, AstraZeneca's largest clinical trial program, EUCLID has randomized more than 13,500 patients globally with peripheral artery disease (PAD); approximately 20 percent are patients in the United States (US) from more than 300 active clinical trial sites across the country. EUCLID is designed to evaluate the effects of ticagrelor (monotherapy) compared to clopidogrel (monotherapy) on cardiovascular (CV) events and safety in PAD patients. Ticagrelor is currently not approved for the treatment of patients with PAD.

Texas Heart Institute doctors at CHI St. Luke's Health Baylor St. Luke's Medical Center, are the first in Texas to have implanted a device designed to seal abdominal aortic aneurysms (AAAs), rather than bridging through the aneurysms using a traditional stent.

Researchers at the University of Colorado Denver | Anschutz Medical Campus, already focused on understanding and minimizing the effects of stroke in children, will receive $3 million as part of a national effort to better understand stroke.

A University of Illinois at Chicago researcher will test whether brain stimulation combined with gait training can improve patients’ ability to walk after a stroke, under a $1.5 million grant from the National Institute of Child Health and Human Development.

In-hospital survival of patients with a ruptured abdominal aortic aneurysm (AAA) is significantly higher in the U.S. than in England, a study published in the March 15 issue of The Lancet showed. The findings offered insights on hospital-level factors that impact outcomes.